论文部分内容阅读
目的观察前列地尔对糖尿病肾病患者24小时尿微量白蛋白(U-Alb)的影响。方法将38例糖尿病肾病患者,随机分为治疗组20例,对照组18例,两组患者根据24小时尿微量白蛋白量分为A组(早期糖尿病肾病组),B组(临床糖尿病肾病组)。两组患者控制血糖、血压、血脂的治疗方法不变,治疗组加用静脉推注前列地尔(凯时)10μg,每日1次,连续14天,对照组不给上述治疗。结果治疗组:A组(早期肾病组)与B组(临床肾病组)治疗后,24小时尿微量白蛋白均较治疗前明显降低;与正常对照组相比明显降低,差异显著。结论前列地尔可减少糖尿病肾病患者的尿蛋白。
Objective To investigate the effect of alprostadil on 24-hour urinary albumin (U-Alb) in patients with diabetic nephropathy. Methods Thirty-eight patients with diabetic nephropathy were randomly divided into treatment group (n = 20) and control group (n = 18). The two groups were divided into group A (early diabetic nephropathy group) and group B ). Two groups of patients control blood sugar, blood pressure, blood lipids treatment unchanged, the treatment group plus intravenous alprostadil (Kay hours) 10μg, day 1, for 14 days, the control group did not give the above treatment. Results After treatment, the urine microalbumin in group A (early nephropathy group) and group B (clinical nephropathy group) were significantly lower than those before treatment, but significantly lower than those in normal control group. Conclusion Alprostadil reduces urinary protein in patients with diabetic nephropathy.